BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case

MD-Onco Pub Date : 2021-12-05 DOI:10.17650/2782-3202-2021-1-1-38-42

M. Davydov, P. A. Zeynalova, A. Fedenko, D. A. Chekiny, E. K. Ibragimov, A. A. Filimonov, O. Sinitsyna, E. Bogush, M. Chekalova, G. Allakhverdieva, M. V. Shamanova, I. V. Zhguleva, V. Y. Kirsanov, V. Ponomarev, S. Polikarpova, T. Valiev, M. A. Kurtser

{"title":"BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case","authors":"M. Davydov, P. A. Zeynalova, A. Fedenko, D. A. Chekiny, E. K. Ibragimov, A. A. Filimonov, O. Sinitsyna, E. Bogush, M. Chekalova, G. Allakhverdieva, M. V. Shamanova, I. V. Zhguleva, V. Y. Kirsanov, V. Ponomarev, S. Polikarpova, T. Valiev, M. A. Kurtser","doi":"10.17650/2782-3202-2021-1-1-38-42","DOIUrl":null,"url":null,"abstract":"Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.","PeriodicalId":318498,"journal":{"name":"MD-Onco","volume":"36 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MD-Onco","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/2782-3202-2021-1-1-38-42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.

查看原文本刊更多论文

双绒毛膜双羊膜双胞胎怀孕期间皮肤braf突变黑色素瘤。临床病例

根据大多数作者的说法，黑色素瘤是怀孕期间最常见的肿瘤(占所有恶性肿瘤的31%)。大约1/3的育龄女性黑色素瘤在怀孕期间或产后被诊断出来。然而，只有一些回顾性研究分析了妊娠对黑色素瘤发展的影响，缺乏braf突变黑色素瘤的发生、进展和治疗的结论性数据。在这一亚群患者中，无论采用何种治疗方法，BRAF状态都可能对疾病结果产生负面影响。本文提出了一个临床病例复发的黑色素瘤与BRAF V600E突变在怀孕期间。患者在妊娠延长期间进行了淋巴结清扫，分娩后接受了МЕК和ВRAF抑制剂的抗肿瘤药物治疗。妊娠期间黑色素瘤复发不会使母体和胚胎的治疗结果恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MD-Onco

自引率

0.00%

发文量